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A b s t r a c t
Background: Heart failure (HF) is a fatal disease. Plasma osmolality with individual impacts of sodium, blood urea nitrogen 
(BUN), and glucose has not been studied prognostically in patients with HF. 
Aim: This study aims to investigate the impact of serum osmolality on clinical endpoints in HF patients.
Methods: A total of 509 patients (383 males, 126 females) with HF with reduced ejection fraction in three HF centres were 
retrospectively analysed between January 2007 and December 2013. Follow-up data were completed for 496 patients. Plasma 
osmolality was calculated as (2 × Na) + (BUN/2.8) + (Glucose/18). Quartiles of plasma osmolality were produced, and the 
possible relationship between plasma osmolality and cardiovascular mortality was investigated.  
Results: The mean follow-up was 25 ± 22 months. The mean age was 56.5 ± 17.3 years with a mean EF of 26 ± 8%. The 
mean levels of plasma osmolality were as follows in the quartiles: 1st % = 280 ± 6, 2nd % = 288 ± 1, 3rd % = 293 ± 2 (95% 
confidence interval [CI] 292.72–293.3), and 4th % = 301 ± 5 mOsm/kg. The EF and B-type natriuretic peptide levels were 
similar in the four quartiles. Univariate and multivariate analyses in the Cox proportional hazard model revealed a significantly 
higher rate of mortality in the patients with hypo-osmolality. The Kaplan-Meier plot showed graded mortality curves with the 
1st quartile having the worst prognosis, followed by the 4th quartile and the 2nd quartile, while the 3rd quartile was shown to 
have the best prognosis. 
Conclusions: Our study results suggest that normal plasma osmolality is between 275 and 295 mOsm/kg. However, being 
close to the upper limit of normal range (292–293 mOsm/kg) seems to be the optimal plasma osmolality level in terms of 
cardiovascular prognosis in patients with HF.
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INTRODUCTION
Chronic heart failure (HF) is a complex clinical syndrome re-
sulting from any structural or functional cardiac disorders that 
impair the systolic ability of the ventricle. Despite available 
therapies, the rates of hospitalisation and death from HF still 
remain unacceptably high [1]. Risk stratification of patients 
with HF is critical. While B-type natriuretic peptide (BNP) 
has its primary implication in guiding HF treatment, it is also 
a relevant marker for the prediction of mortality in HF patients 
[2]. On the other hand, the routine measurement of BNP is 
costly and it is not routinely performed in clinical practice. 
The plasma osmolality, which is a useful marker of hy-
dration status, is carefully managed by the body, measuring 
the fluid and electrolyte balance of the body [3]. The plasma 
glucose, blood urea nitrogen (BUN), and sodium are the main 
components of plasma osmolality. In HF patients, recognition 
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of the predictors of poor outcome is of utmost importance 
because this may help the physician to decide on the most 
appropriate therapy. 
To the best of our knowledge, there is no study investigat-
ing the prognostic value of plasma osmolality with individual 
impacts of sodium, BUN, and glucose in patients with HF. In 
this study, therefore, we aimed to investigate the impact of 
serum osmolality on clinical endpoints in HF patients. 
METHODS
A total of 509 patients with HF with reduced ejection fraction 
(HFrEF) in three HF centres were retrospectively analysed be-
tween January 2007 and December 2013. Patients older than 
18 years with an EF of ≤ 35% and BNP level of > 35 pg/mL 
were included in the study. Pregnant women, patients with 
acute myocardial ischaemia within the past 30 days, acute 
myocarditis, cancer and/or a life expectancy of less than 
one year, and those with missing results for sodium, plasma 
glucose, BUN, or BNP within the first 8 h of admission 
were excluded.
Data about patients and current medication were ob-
tained from the records of hospitals. Within 8 h of admission, 
blood samples were collected using a needle and syringe 
and transferred to collection tubes, which were immediately 
inverted several times. The samples were then analysed. The 
equation for serum osmolality involved the sum of multiples 
of serum sodium, glucose, and BUN. It was calculated as 
(2 × Na) + (BUN/2.8) + (Glucose/18). The osmolality was 
assessed in miliosmoles per kilogram. Normal plasma osmo-
lality was defined as being between 275 and 295 mOsm/kg 
[4]. The patients were stratified by quartiles of admission 
osmolality with low osmolality (the first quartile) and high 
osmolality (the fourth quartile). The mortality in four patient 
groups was defined as hypo-osmolar, normo-hypo-osmolar, 
normo-hyperosmolar, and hyperosmolar based on the plasma 
osmolality. The clinical outcomes were compared between 
those groups. Other laboratory results, clinical characteristics, 
cardiovascular (CV) risk factors, comorbidities, and medica-
tions were recorded.
Following the index visit, CV death-related outcomes dur-
ing follow-up were assessed by an independent investigator, 
who gathered and reviewed the hospital’s medical records and 
made necessary phone calls for collecting data. The follow-up 
data were complete in 496 patients for CV death.
In addition, CV death was defined as death due to acute 
coronary syndrome (ACS), sudden death, HF, or stroke. Hyper-
tension was defined as a blood pressure of > 140/90 mm Hg 
on more than two occasions during office measurements or 
being on anti-hypertensive treatment. Diabetes mellitus was 
defined as a fasting blood glucose of ≥ 126 mg/dL or being on 
anti-diabetic treatment. Coronary artery disease (CAD) was 
defined as a previous clinical history of CAD or a documented 
coronary stenosis of > 50%. Functional classification was 
made according to the New York Heart Association functional 
classification, which provides a simple way of classifying the 
extent of HF [5].
Echocardiographic measurements were obtained in ac-
cordance with the recommendations of the American Society 
of Echocardiography. The wall thickness and chamber sizes 
were measured on transthoracic echocardiograms. The left 
ventricular EF (LVEF) was measured using the Simpson 2S 
biplane method [6].
Written, informed consent was obtained from each 
patient. The study protocol was approved by the local Ethics 
Committee. The study was conducted in accordance with the 
principles of the Declaration of Helsinki for Human Research.
Statistical analysis
Statistical analysis was performed using SPSS version 
14.0 software (SPSS Inc., Chicago, IL, USA). The Kolmog-
orov-Smirnov test was used to verify the normality of the 
distribution of continuous variables. Abnormally distributed 
continuous variables were expressed in mean ± standard 
deviation (SD) or median (min–max), while categorical vari-
ables were presented as percentages. The c2 or Fisher’s exact 
tests were used for the intergroup analysis. Independent t-test 
was used for normally distributed continuous variables, while 
the Mann-Whitney U test was applied for abnormally distrib-
uted variables. Univariate analysis was done to quantify the 
association of variables with mortality. Significant variables in 
the univariate analysis and other potential confounders were 
included in the multivariate Cox proportional hazard model 
with the forward stepwise method to determine the independ-
ent prognostic factors for mortality. The Kaplan-Meier curves 
were used to display the mortality in four patient groups. 
A p value of 0.05 was considered statistically significant.
RESULTS
The mean follow-up was 25 ± 22 months (up to 111 months). 
Baseline characteristics including CV risk factors, medications 
used, and laboratory findings are shown in Table 1. The mean 
age of the study population was 56 ± 17 years. Of 496 patients, 
378 were males and 118 patients were females. The mean 
EF was 26 ± 8%. The median level of BNP was 240 pg/mL. 
The mean levels of plasma osmolality were clas-
sified in quartiles: mean osmolality in the 1st quartile 
280 ± 6.2 mOsm/kg, in the 2nd quartile 288 ± 1 mOsm/kg, 
in the 3rd quartile 293 ± 2 mOsm/kg, and in the 4th quartile 
301 ± 5 mOsm/kg. The 1st quartile was also defined as the 
hypo-osmolar group (n = 124), the 2nd and 3rd quartiles were 
defined as normo-osmolar groups (n = 248), and the 
4th quartile was defined as the hyper-osmolar group (n = 124). 
The EF and BNP levels were similar in the four subgroups. The 
mean age, systolic blood pressure, fasting glucose levels, BUN, 
creatinine, sodium, and triglyceride levels were significantly 
different among the four quartiles of osmolality. The patients 
in the 4th quartile were older with higher creatinine levels than 
the other quartiles of osmolality. 
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Table 1. Baseline characteristics of study patients and laboratory findings and medications
Variable Hypo-osmolar 
(n = 124)




osmolar (n = 124)
Normo-hyper- 
osmolar (n = 124)
Baseline characteristics
Mean age [years] 57 ± 17 53 ± 17 55 ± 17 61 ± 17 0.003
Male/Female 91/33 90/34 97/27 100/24 0.381
Hypertension 75 (61%) 59 (48%) 63 (51%) 78 (63%) 0.041
Diabetes mellitus 19 (15%) 26 (21%) 29 (23%) 40 (32%) 0.015
Coronary artery disease 106 (85%) 93 (75%) 107 (89%) 78 (63%) 0.045 
Disease duration [months] 27 ± 26 20 ± 18 33 ± 41 27 ± 29 0.223
Heart rate [bpm] 75 ± 31 82 ± 25 82 ± 26 77 ± 31 0.328
Systolic blood pressure [mm Hg] 109 ± 23 116 ± 20 122 ± 26 120 ± 26 0.011
Diastolic blood pressure [mm Hg] 73 ± 13 76 ± 14 78 ± 14 79 ± 14 0.057
NYHA class 3–4 26 (21%) 20 (16%) 31 (25%) 17 (14%) 0.105
Atrial fibrillation 33 (27%) 17 (14%) 23 (19%) 32 (26%) 0.035
LVEF [%] 25 ± 8 27 ± 8 26 ± 8 27 ± 9 0.382
Primary end point
Cardiovascular mortality 63 (51%) 36 (29%) 28 (23%) 47 (38%) < 0.001
Laboratory findings
Osmolality 280.1 ± 6.1 288.5 ± 1.4 293.2 ± 1.6 301.2 ± 5.4 < 0.001
Fasting glucose [mg/dL] 109 ± 17 117 ± 46 118 ± 45 138 ± 77 < 0.001
Blood urea nitrogen [mg/dL] 23 ± 12 20 ± 9 26 ± 17 34 ± 22 < 0.001
Creatinine [mg/dL] 1.05 ± 0.4 1.04 ± 0.5 1.16 ± 0.4 1.43 ± 0.7 < 0.001
Sodium [mEq/L] 133 ± 4 137 ± 2 139 ± 3 141 ± 4 < 0.001
Potassium [mEq/L] 4.4 ± 0.6 4.5 ± 0.5 4.5 ± 0.5 4.7 ± 0.7 0.008
Haemoglobin [g/dL] 13.1 ± 2 13.5 ± 2 13.5 ± 2 13.8 ± 2 0.068
B-type natriuretic peptide > 240 pg/mL 32 (55%) 28 (34%) 24 (29%) 17 (28%) 0.005
Total cholesterol [mg/dL] 149 ± 49 169 ± 51 173 ± 47 162 ± 46 0.001
HDL cholesterol [mg/dL] 33 ± 13 38 ± 12 38 ± 11 36 ± 11 0.009
LDL cholesterol [mg/dL] 96 ± 36 107 ± 43 105 ± 37 99 ± 33 0.066
Triglyceride [mg/dL] 108 ± 65 123 ± 73 146 ± 86 135 ± 87 0.002
Alanine aminotransferase [IU/L] 71 ± 151 28 ± 21 38 ± 85 36 ± 36 0.155
Aspartate aminotransferase [IU/L] 60 ± 114 29 ± 17 35 ± 86 32 ± 19 0.007
Medication
Antiplatelet agents 62 (50%) 67 (54%) 67 (54%) 67 (54%) 0.895
Beta-blockers 76 (61%) 91 (73%) 81 (65%) 114 (92%) < 0.001
ACE inhibitor/ARB 77 (62%) 94 (76%) 100 (81%) 101 (82%) 0.001
Digoxin 65 (52%) 56 (45%) 59 (48%) 59 (48%) 0.710
Diuretics 78 (63%) 78 (63%) 71 (57%) 80 (65%) 0.895
Mineralocorticoid receptor antagonist 79 (64%) 82 (66%) 83 (67%) 85 (69%) 0.879
ACE — angiotensin-converting enzyme; ARB — angiotensin receptor blocker; HLD — high-density lipoprotein; LDL — low-density lipoprotein; 
LVEF — left ventricular ejection fraction; NYHA — New York Heart Association
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Figure 1. Kaplan-Meier curves for cardiovascular mortality
Table 2. Univariate and multivariate analyses of mortality
Univariate Multivariate
p HR 95% CI p HR 95% CI
Statistically significant variables
Hypo-osmolality < 0.001 2.428 1.602–3.682 0.021 1.651 1.077–2.530
Normo-hyperosmolality 0.001 0.451 0.282–0.722
Mean age [years] < 0.001 1.026 1.015–1.038
NYHA class 3–4 0.004 1.944 1.232–3.065
Atrial fibrillation 0.001 2.050 1.323–3.178
LVEF [%] 0.046 0.977 0.955–1.000
Creatinine [mg/dL] < 0.001 2.181 1.494–3.185
Haemoglobin [g/dL] 0.002 0.856 0.775–0.945
B-type natriuretic peptide > 240 pg/mL < 0.001 6.367 3.602–11.257
Total cholesterol [mg/dL] < 0.001 0.990 0.986–0.995
HDL cholesterol [mg/dL] < 0.001 0.960 0.943–0.977
Triglyceride [mg/dL] < 0.001 0.990 0.987–0.994 0.007 1.002 1.001–1.004
Alanine aminotransferase [IU/L] 0.020 1.006 1.001–1.011
Aspartate aminotransferase [IU/L] 0.016 1.013 1.002–1.023
Beta-blockers usage 0.003 1.841 1.227–2.764
Variables which correlated with osmolality 
Normo-hypo-osmolality 0.104 0.694 0.446–1.078
Hyperosmolality 0.447 1.178 0.773–1.795
Hypertension  0.155 1.312 0.903–1.907
Diabetes mellitus 0.118 1.409 0.917–2.164
Coronary artery disease 0.645 1.122 0.688–1.828
Systolic blood pressure [mm Hg] 0.413 0.995 0.983–1.007
Potassium [mEq/L] 0.821 1.036 0.761–1.412
ACE inhibitor/ARB usage 0.744 1.073 0.702–1.639
All the variables from Table 1 were examined and only those significant at a p < 0.05 level and those with a correlated osmolality are shown in 
univariate analysis. The multivariate Cox proportional hazard model with forward stepwise method included all univariate predictors and those 
with correlated osmolality level. ACE — angiotensin-converting enzyme; ARB — angiotensin receptor blocker; CI — confidence interval;  
HDL — high-density lipoprotein; LVEF — left ventricular ejection fraction; NYHA — New York Heart Association; OR — odds ratio
Univariate and multivariate predictors of mortality 
included into the Cox proportional hazard model are pre-
sented in Table 2. This model revealed a significantly higher 
rate of mortality in the patients with hypo-osmolality. The 
Kaplan-Meier plot yielded graded mortality curves with 
the 1st quartile having the worse prognosis, followed by the 
4th and the 2nd quartiles, while the 3rd quartile was shown to 
have the best prognosis (Fig. 1). 
DISCUSSION
The main finding of the present study is the association 
between the serum osmolality and mortality in hospitalised 
patients with HFrEF. Admission osmolality in the lowest quar-
tile was highly and independently predictive of mortality in 
this patient population. 
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levels in HF patients predict a higher in hospital-mortality, 
low osmolality not due to high BUN levels can be a marker 
of worse prognosis. Low levels of BUN are less common in 
HF patients; however, they may be caused by malabsorption 
or abnormal liver functions due to congestion or low muscle 
mass related with advanced disease. 
The main advantages of using serum osmolality in clinical 
practice include the utilisation of standardised and objective 
analytic procedures without any requirement for additional 
and nutritional data [28]. In addition, serum samples contain 
numerous substances (i.e. chloride, potassium, and bicarbo-
nate), which constitute 95% of total osmolality. Although they 
are found in small amounts, proteins also affect total serum 
osmolality. Furthermore, there are individual differences in se-
rum protein concentrations. Serum osmolality is primarily done 
to investigate hyponatraemia. Serum sodium levels can be low 
when the presence of water in the blood decreases due to the 
presence of increased protein or lipids [29, 30]. On the other 
hand, all osmolality calculations were made according to a sin-
gle fasting blood sample. Many equations have been used to 
calculate osmolality, but which serum osmolality equation best 
predicts serum osmolality is unclear. Osmolality is dynamic and 
can fluctuate as the body responds to and corrects temporary 
water imbalances. Osmolality results are not diagnostic, while 
they only suggest that a person has an imbalance. Lastly, further 
investigations are needed to confirm our results.
Despite the limitations of the study, our results suggest that 
the serum osmolality of HF patients on admission to hospital 
is a good prognostic marker. In our study, all the components 
of serum osmolality (i.e. glucose, BUN, sodium levels) were 
significantly different among the four osmolality quartiles with 
lower levels in the first quartile showing worse prognosis. In 
our study, serum osmolality was found to predict prognosis 
independently of EF, functional capacity, and BNP levels. It is 
well-known that functional capacity is a powerful determinant 
of outcomes, and it is an important prognostic marker in routine 
clinical use. Also, BNP levels predict the functional capacity 
in HF patients [31]. Unlike BNP levels, serum osmolality can 
predict the prognosis independently of the functional status.
CONCLUSIONS
In conclusion, our study results suggest that normal plasma 
osmolality is between 275 and 295 mOsm/kg. However, being 
close to the upper limit of normal range (292–293 mOsm/kg) 
seems to be the optimal plasma osmolality level in terms of 
CV prognosis in patients with HF. We believe that osmolality is 
a feasible and cost–effective predictor of mortality in patients 
with HF. However, further studies are needed both to establish 
a conclusion and to elucidate the exact role of osmolality in 
guiding HF therapy.
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Although all the components of serum osmolality sepa-
rately have a prognostic value in patients with HF, reduced 
serum osmolality in this group can mainly be associated with 
hyponatraemia with euvolaemia or hyponatraemia with 
hypervolaemia coupling [7]. Hyponatraemia is defined as 
serum sodium concentration lower than 136 mmol/L. It is 
the most common electrolyte disorder in the clinical setting 
in hospitalised HF patients [8]. Many patients with HF have 
reduced sodium levels due to neurohormonal activation 
or the effects of medications [9]. Chronic activation of the 
renin–angiotensin–aldosterone system with the stimulation 
of sympathetic nervous system as a response to inadequate 
tissue perfusion stimulates water and sodium retention. To 
increase the intravascular volume, arginine vasopressin is 
released as a response to low cardiac output. Arginine vaso-
pressin plays a key role in the development of hyponatraemia 
in HF [10, 11]. A number of clinical studies have confirmed 
the association of hyponatraemia with increased morbidity 
and mortality in hospitalised patients with HF [12–15]. In our 
study, serum sodium levels were significantly different among 
the four osmolality quartile groups with lower values in the 
hypo-osmolar group. 
Another component of serum osmolality is the serum 
glucose level. Hypo-osmolality due to hypoglycaemia may 
have deleterious effects on survival in patients with HF. Al-
though high glucose levels are well-known to increase the 
risk of HF irrespective of other traditional risk factors and 
ischaemia [16], low glucose levels are found to be associ-
ated with a higher risk of in-hospital mortality [17]. Hypo-
glycaemia during the course of congestive HF may result 
from reduced hepatic glucose output by poor diet, poor 
glucose absorption, and impaired hepatic glycogenolysis 
and gluconeogenesis [18]. Chronic, passive, long-standing 
congestion of the liver is a common feature and hypo-
glycaemia secondary to hepatic dysfunction arising from 
chronic passive congestion of the liver is not uncommon. 
Recognition and treatment of hypoglycaemia are obviously 
of utmost importance during the course of congestive HF. 
In most cases, the improvement of HF necessitates the cor-
rection of hypoglycaemia [19]. In our study, hypo-osmolar 
patients who had worse prognosis had statistically significant 
lower glucose levels.
In addition, renal dysfunction, a common finding in HF, 
has emerged as one of the most potent indicators in these 
patients [20]. Patients with renal dysfunction during HF 
hospitalisation have higher in-hospital mortality rates, longer 
length of stay, and increased long-term mortality rates [21–23]. 
Urea also plays a basic and direct role in the fluid and sodium 
homeostasis, which is regulated by the neurohormonal system 
[24]. Increased BUN levels may indicate adrenergic activa-
tion, activation of the renin–angiotensin–aldosterone system, 
and increased vasopressin levels [25–27]. Although high BUN 
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Osmolalność osocza jako czynnik predykcyjny 
śmiertelności u chorych z niewydolnością serca 
i obniżoną frakcją wyrzutową
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S t r e s z c z e n i e
Wstęp: Niewydolność serca (HF) jest chorobą śmiertelną. Nie prowadzono dotychczas prognostycznych badań nad osmolalnoś-
cią osocza, wraz z indywidualnym wpływem na stężenie sodu, azotu mocznikowego we krwi (BUN) i glukozy, u chorych na HF. 
Cel: Celem niniejszego badania była ocena wpływu osmolalności osocza na kliniczne punkty końcowe u chorych z HF.
Metody: Do badania włączono 509 pacjentów (383 mężczyzn, 126 kobiet) z HF i obniżoną frakcją wyrzutową z trzech ośrod-
ków kardiologicznych, a ich dane analizowano retrospektywnie w okresie od stycznia 2007 r. do grudnia 2013 r. Kompletne 
dane z obserwacji zebrano od 496 chorych. Osmolalność osocza obliczano wg wzoru: (2 × Na)+(BUN/2,8)+(glukoza/18). 
Dokonano podziału na grupy w zależności od kwartyli osmolalności osocza i analizowano możliwe zależności między osmo-
lalnością osocza a śmiertelnością sercowo-naczyniową.
Wyniki: Okres obserwacji trwał średnio 25 ± 22 miesiące. Średni wiek badanych wynosił 56,5 ± 17,3 roku, a średnia frakcja 
wyrzutowa — 26 ± 8%. Średnie poziomy osmolalności osocza miały następujące wartości w poszczególnych kwartylach: 
1. kwartyl % = 280 ± 6, 2. kwartyl% = 288 ± 1, 3. kwartyl % = 293 ± 2 (95% przedział ufności 292,72–293,3), 4. kwartyl 
% = 301 ± 5 mOsm/kg. Wartości frakcji wyrzutowej i peptydu natriuretycznego typu B były podobne dla wszystkich kwartyli. 
Jedno- i wieloczynnikowe analizy w modelu proporcjonalnego hazardu Coxa wykazały istotnie wyższą śmiertelność u chorych 
z hipoosmolalnością osocza. W analizie Kaplana-Meiera uzyskano krzywe proporcjonalnych wartości wskaźnika śmiertelności, 
przy czym najgorsze rokowanie wiązało się z 1. kwartylem osmolalności osocza, nieco lepsze było kolejno dla 4. i 2. kwartylu, 
a najlepsze rokowanie wiązało się z 3. kwartylem. 
Wnioski: Wyniki badania sugerują, że prawidłowe wartości osmolalności osocza mieszczą się w zakresie od 275 do 
295 mOsm/kg. Jednak wydaje się, że optymalne wartości tego parametru w odniesieniu do rokowania u chorych z HF są 
zbliżone do górnego zakresu wartości prawidłowych (292–293 mOsm/kg).
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